Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Core Insights - Immunome, Inc. is set to host a conference call and webcast on December 15, 2025, to disclose topline results from the Phase 3 RINGSIDE trial of varegacestat, a gamma secretase inhibitor for desmoid tumors [1][2] Company Overview - Immunome is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies [3] - The company has a portfolio that includes varegacestat, a late-clinical stage gamma secretase inhibitor, IM-1021, a clinical-stage ROR1 antibody-drug conjugate (ADC), and IM-3050, a FAP-targeted radiotherapy that has received IND clearance [3] - Immunome is also advancing a range of early-stage ADCs targeting undisclosed solid tumor indications [3]